Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)Completed
NCT04106544NAUpdated Aug 16, 2023
Sponsor: Sanofi
Sphingomyelin Lipidosis
United States, Argentina, Belgium, Brazil, Chile +8 more
A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy ParticipantsCompleted
NCT05976360Phase 1Updated Aug 4, 2023
Sponsor: Sanofi
Healthy Volunteer
United States
A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.Completed
NCT05976373Phase 1Updated Aug 4, 2023
Sponsor: Sanofi
Healthy Volunteers
United States
A Study of PRN1008 in Patients With PemphigusTerminated
NCT03762265Phase 3Updated Aug 2, 2023
Sponsor: Principia Biopharma, a Sanofi Company
Pemphigus
United States, Argentina, Australia, Brazil, Bulgaria +14 more
Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS ProgramCompleted
NCT03954717N/AUpdated Aug 2, 2023
Sponsor: Shepherd Center, Atlanta GA
Multiple Sclerosis
United States
Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter StudyRecruiting
NCT05950750N/AUpdated Jul 18, 2023
Sponsor: Turkish Hematology Association
TTP - Thrombotic Thrombocytopenic Purpura
Turkey (Türkiye)
Real World Study on the Use of Cemiplimab in Adult Patients in UKCompleted
NCT05493826N/AUpdated Jul 14, 2023
Sponsor: Sanofi
Cutaneous Squamous Cell Carcinoma
United Kingdom
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM PatientsCompleted
NCT01749969Phase 1Updated Jul 13, 2023
Sponsor: Sanofi
Plasma Cell Myeloma
United States
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced MalignanciesTerminated
NCT03637764Phase 1, Phase 2Updated Jul 10, 2023
Sponsor: Sanofi
Neoplasm
United States, Belgium, Canada, Czechia, Italy +3 more
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)Completed
NCT03633617Phase 3Updated Jun 28, 2023
Sponsor: Regeneron Pharmaceuticals
Eosinophilic Esophagitis
United States, Australia, Belgium, Canada, France +7 more
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host DiseaseCompleted
NCT02841995Phase 2Updated Jun 28, 2023
Sponsor: Kadmon, a Sanofi Company
Graft vs Host Disease
United States
A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female SubjectsCompleted
NCT05918614Phase 1Updated Jun 26, 2023
Sponsor: Kadmon, a Sanofi Company
Immune System Disorder (Healthy Volunteer)
United States
A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male SubjectsCompleted
NCT05918627Phase 1Updated Jun 26, 2023
Sponsor: Kadmon, a Sanofi Company
Immune System Disorder (Healthy Volunteer)
United States
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompleted
NCT03989115Phase 1, Phase 2Updated Jun 26, 2023
Sponsor: Revolution Medicines, Inc.
Solid Tumor
United States, South Korea
A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female SubjectsCompleted
NCT05918588Phase 1Updated Jun 26, 2023
Sponsor: Kadmon, a Sanofi Company
Immune System Disorder (Healthy Volunteer)
United States
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic SclerosisTerminated
NCT04680975Phase 2Updated Jun 5, 2023
Sponsor: Kadmon, a Sanofi Company
Diffuse Cutaneous Systemic Sclerosis
United States
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsTerminated
NCT00227617Phase 2, Phase 3Updated May 22, 2023
Sponsor: University of California, San Francisco
Gastrointestinal Carcinoid Tumor · Islet Cell Tumor · Lung Cancer · Neoplastic Syndrome
United States
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)Completed
NCT03275454Phase 1Updated May 18, 2023
Sponsor: Bioverativ, a Sanofi company
Purpura, Thrombocytopenic, Idiopathic
United States, Germany, United Kingdom
Dengue Effectiveness Study in the PhilippinesCompleted
NCT03803618N/AUpdated May 17, 2023
Sponsor: University of the Philippines
Dengue · Severe Dengue · Virologically Confirmed Dengue
Philippines
Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired PneumoniaTerminated
NCT02332577Phase 4Updated May 8, 2023
Sponsor: Sanofi
Pneumonia
France, Tunisia
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCompleted
NCT03510884Phase 3Updated May 6, 2023
Sponsor: Sanofi
Hypercholesterolaemia
United States, Argentina, Austria, Brazil, Bulgaria +19 more
Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical CourseCompleted
NCT02301572N/AUpdated May 3, 2023
Sponsor: Weill Medical College of Cornell University
Multiple Sclerosis
United States
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic DermatitisCompleted
NCT04287608N/AUpdated Apr 28, 2023
Sponsor: Regeneron Pharmaceuticals
Conjunctivitis · Atopic Dermatitis
United States
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 MonthsCompleted
NCT05832333N/AUpdated Apr 27, 2023
Sponsor: Sanofi
Influenza
South Korea
To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisCompleted
NCT03856619Phase 4Updated Apr 19, 2023
Sponsor: Sanofi
Relapsing Multiple Sclerosis
India

Previous page Next page